BioNTech settles vaccine patent suit with GSK after CureVac purchase
BioNTech and Pfizer have reached a $500 million settlement with GlaxoSmithKline in patent infringement litigation related to mRNA vaccines for COVID-19 and the flu, including a non-exclusive patent license, following the...To view the full article, register now.
Already a subscriber? Click here to view full article